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Abstract
Introduction: Neoangiogenesis appears to be an important event in tumour invasion and in the formation of metastases in many endocrine-
-related human cancers. Vascular endothelial growth factor (VEGF) is a glycoprotein with potent angiogenic, mitogenic and vascular
permeability-enhancing activities specific for endothelial cells and acts through VEGF receptors. The aim of the study was to evaluate the
plasma blood concentrations of VEGF, sVEGFR1, and sVEGFR2 in patients with benign and malignant adrenal tumours treated by surgery.
Material and methods: We studied the blood before surgery of 41 patients with adrenal cortex tumours and 10 normal subjects without
hormonal or CT/USG pathology of the adrenal glands (controls). We studied the blood after adrenalectomy of 16 patients with tumours of
the adrenal cortex.
Results: Concentrations of VEGF, sVEGFR1 and sVEGFR2 in blood plasma before as well as 30 days after surgery were evaluated by
ELISA. VEGF blood concentrations before surgery did not differ in the patients with the cortical tumours as compared to the controls. After
surgery VEGF concentrations decreased among the patients, taken in total, with adrenal cortex tumours and cortical adenomas. Before
surgery sVEGFR1 blood concentrations were increased in the patients with Conn’s syndrome only in comparison with the controls. After
surgery, sVEGFR1 concentrations decreased significantly in the group with cortical adenomas only. Before and after surgery sVEGFR2
blood concentrations did not differ between the groups of patients studied and the controls.
Conclusions: Peripheral blood concentrations of VEGF and its receptors cannot be clinically valuable markers that discriminate between
benign and malignant adrenocortical tumours before and after adrenalectomy. (Pol J Endocrinol 2009; 60 (1): 9–13)
Key words: adrenal cortex tumours, adrenalectomy, vascular endothelial growth factor, soluble vascular endothelial growth factor receptor 1,
soluble vascular endothelial growth factor receptor 2, angiogenesis, oncogenesis
Streszczenie
Wstęp: Neoangiogeneza należy do kluczowych mechanizmów patologicznych w przebiegu choroby nowotworowej gruczołów dokrew-
nych, w tym kory nadnerczy. Naczyniowo-śródbłonkowy czynnik  wzrostu (VEGF, vascular endothelial growth factor), po aktywacji specy-
ficznych receptorów w komórkach endothelium, wykazuje działanie angiogenne, mitogenne i zwiększa przepuszczalność ścian naczyń
krwionośnych. Celem pracy było zbadanie stężeń VEGF, sVEGFR1 i sVEGFR2 we krwi obwodowej u chorych z guzami kory nadnerczy
o charakterze łagodnym i złośliwym poddanych adrenalektomii.
Materiał i metody: Przed leczeniem operacyjnym zbadano krew u 41 pacjentów z guzami kory nadnerczy oraz u 10 osób zdrowych bez
zmian hormonalnych i obrazowych (USG/CT) nadnerczy (grupa kontrolna). Po adrenalektomii zbadano ponownie krew u 16 chorych.
Wyniki: Stężenia VEGF, VEGFR1 i VEGFR2 zbadano w osoczu krwi przed i po 30 dniach od operacji metodą ELISA. Przed operacją
stężenia VEGF we krwi nie różniły się pomiędzy całą grupą pacjentów z guzami kory nadnerczy a grupą kontrolną. Po leczeniu chirurgicz-
nym średnie stężenia VEGF zmniejszyły się w całej grupie operowanych chorych i w podgrupie z gruczolakami kory. Stężenia VEGF R1
przed operacją były wyższe tylko w grupie chorych z zespołem Conna, a po adrenalektomii obniżyły się tyko w podgrupie osób z gruczola-
kami kory. Stężenia VEGFR2 nie różniły się pomiędzy wszystkimi badanymi grupami oraz przed i po operacji.
Wnioski: W praktyce klinicznej oznaczanie stężeń VEGF, VEGFR1 i VEGFR2 we krwi obwodowej u chorych z nowotworami nadnerczy
nie pozwala na rozpoznanie guzów kory nadnerczy o charakterze złośliwym. (Endokrynol Pol 2009; 60 (1): 9–13)
Słowa kluczowe: guzy kory nadnerczy, naczyniowo-śródbłonkowy czynnik wzrostu, receptory (1 i 2) dla naczyniowo-śródbłonkowego czynnika
wzrostu, angiogeneza, onkogeneza
10
Angiogenic markers and adrenal cortex tumours  Jolanta Jurczyńska et al.
PR
A
C
E 
O
R
Y
G
IN
A
LN
E
Introduction
The growth of microvessel sprouts from pre-existing
vasculature is generally termed angiogenesis [1]. Focal
angiogenesis plays a pivotal role in physiological pro-
cesses such as wound healing, ovulation and placenta-
tion [2]. Neoangiogenesis, a multistep process, appears
to be an important event in tumour invasion and in the
formation of metastases in many human oncogenesis,
including adrenal neoplasia [3–5]. Sprouts of new ves-
sels grow mainly by the migration of endothelial cells
[6], and vascular endothelial growth factor (VEGF) is
one of the most active pro-angiogenic factors. VEGF is
a homodimeric 34–42 kDa, heparin-binding glycopro-
tein with potent angiogenic, mitogenic and vascular
permeability-enhancing actions specific for endothelial
cells [7]. Elevated levels of VEGF have been reported in
the synovial fluid of rheumatoid arthritis patients and
in sera from cancer patients [2]. VEGF acts through
VEGF receptors (R1, R2, and R3). VEGF and soluble
VEGF receptors (sVEGFR1, and sVEGFR2) represent
a regulatory system essential for both normal and pa-
thological angiogenesis. The signalling pathway after
the binding of VEGF to its receptor includes dimerisa-
tion and activation of tyrosine kinases [8]. Administra-
tion of recombinant soluble VEGFR1 or VEGFR2 inhi-
bits angiogenesis in the retina, corpus luteum and tu-
mours [9–11].
Neoangiogenesis (evaluated as tumour vessel den-
sity) has been recognized as a key process in the deve-
lopment of many types of human neoplasia [2], inclu-
ding breast, bladder, and stomach cancers, and is asso-
ciated with the development of metastases [12, 13], poor
prognosis [14, 15] and reduced survival [16, 17].
The aim of the study was to evaluate the plasma blo-
od concentration of VEGF, sVEGFR1, and sVEGFR2 in
patients with benign and malignant adrenocortical tu-
mours treated by surgery and in normal subjects.
Material and methods
Before surgery we studied 26 females (aged from 28 to
72 years; 59.7 ± 4.23) and 15 males (aged from 51 to
76 years; 62.0 ± 10.7) with adrenal cortex tumours [hi-
stopathological examination: Conn’s syndrome — 7 ca-
ses, cortical adenoma — 22, malignant tumours — 6 (cor-
tical carcinoma — 2, metastatic renal carcinoma — 2,
metastatic malignant melanoma — 1, metastatic adreno-
carcinoma of the colon — 1), myelolipoma — 3, nodular
hyperplasia — 2, normotypical adrenal cortex — 1,
and 10 apparently “healthy” normal subjects without
hormonal or CT/USG pathology of the adrenal glands
(controls: 6 females aged from 36 to 59 years, 50.8 ± 8.7
and 4 males aged from 40 to 60 years, 47.5 ± 8.7). After
adrenalectomy we studied the blood of 16 patients with
adrenal cortex tumours (Conn’s syndrome — 4, corti-
cal adenoma — 8, cortical carcinoma — 2, nodular hy-
perplasia — 1, normotypical adrenal cortex — 1).
Concentrations (pg/ml) of VEGF (sensitivity
— 9.0 pg/mL; intra-assay precision — 6.7%), sVEGF R1
(sensitivity — 3.5 pg/mL, intra-assay precision — 2.6%),
and sVEGF R2 (sensitivity — 4.6 pg/mL, intra-assay pre-
cision — 2.9%) in blood plasma before as well as 30 days
after surgery were evaluated by ELISA (R & D Systems,
USA). All the subjects gave their informed consent to
participation in the study, which was approved by the
Ethics Committee of the Medical University of Łódź.
All comparisons were carried out using Statgraphics
Centurion XIV software. Statistical verifications were
performed using the Kolmogorov-Smirnov normality
test. The statistical significance of differences between
the groups was determined by ANOVA followed by the
least significant difference test (LSD) and Student’s pa-
ired t-tests. The values are presented as the mean ± SEM.
P value £ 0.05 or less was considered statistically signi-
ficant.
Results
Before surgery VEGF blood concentrations (Fig. 1.)
did not differ in the patients with cortical tumours, ta-
ken as whole, (n = 41; 118.10 ± 17.46, NS), cortical ade-
nomas (n = 22; 120.10 ± 16.92, NS), Conn’s syndrome
(n = 7; 98.43 ± 30.83, NS) or malignant tumours of the
adrenal cortex (n = 6; 179.02 ± 94.84, NS) as compared
to the controls (n = 10; 98.78 ± 17.56). After surgery
VEGF concentrations (Fig. 1.) decreased significantly in
all 16 patients studied with adrenal cortex tumours
(43.94 ± 8.12 vs. 145.82 ± 24.72; p < 0.001) and cortical
adenomas (43.43 ± 9.36 vs. 144.90 ± 32.48; p < 0.05) but
showed no significant difference in the cases of Conn’s
syndrome (30.75 ± 7.38 vs. 71.50 ± 26.75, NS) and carci-
nomas of the adrenal cortex (76.25 ± 62.25 vs. 155.95 ±
± 76.25, NS).
Before surgery sVEGF R1 blood concentrations (Fig. 2.)
were increased only in the patients with Conn’s syn-
drome (n = 7; 89.60 ± 11.14; p < 0.05) and were witho-
ut significant change in the subjects with cortical tumo-
urs of all types (n = 41; 75.97 ± 4.05, NS), cortical ade-
nomas (n = 22; 75.90 ± 5.69, NS) and malignant tumo-
urs of the adrenal cortex (n = 6; 65.48 ± 8.11, NS) in
comparisons with controls (n = 10; 59.17 ± 3.85). After
surgery sVEGFR1 concentrations (Fig. 2.) decreased
significantly only in the group with cortical adenomas
(54.59 ± 8.86 vs. 82.60 ± 12.10; p < 0.05) and showed no
significant difference for all 16 patients studied (62.85 ±
± 5.02 vs. 79.13 ± 8.29, NS), those with Conn’s syndro-
me (73.60 ± 11.36 vs. 100.93 ± 15.72, NS) or those with
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carcinomas of the adrenal cortex (62.25 ± 3.15 vs. 76.40 ±
± 19.50, NS).
Before surgery sVEGFR2 blood concentrations did
not differ between the patients with all types of cortical
tumour (n = 41; 9971.34 ± 340.73, NS), those with corti-
cal adenomas (n = 22; 10437.05 ± 506.87, NS), those with
Conn’s syndrome (n = 7; 8657.43 ± 686.73, NS) or tho-
se with malignant tumours of the adrenal cortex (n = 6;
9796.67 ± 895.44, NS) and the controls (n = 10; 9681.00
± 524.91). After surgery sVEGFR2 concentrations did
not show any significant change in the 16 patients stu-
died in total (11065.28 ± 352.36 vs. 10132.61 ± 531.40, NS)
and in subjects with adrenal adenomas (11330.63 ±
± 349.62 vs. 11376.88 ± 836.42; NS), Conn’s syndrome
(9761.25 ± 422.36 vs. 8194.25 ± 556.15; NS) or carcino-
mas of the adrenal cortex (10062.50 ± 12.50 vs. 9675.00 ±
± 775.00, NS).
Discussion
Adrenal carcinomas are rare, with an estimated preva-
lence of 4–12 per million population [18]. A recent com-
puted tomography study reported an overall 4.4% pre-
valence rate of adrenal lesions [19]. Because prognoses
for adrenocortical adenomas and adrenal carcinomas
are vastly different, it is important to differentiate accu-
rately between the two tumour types. It is generally and
widely accepted that angiogenesis, the multistep pro-
Figure 1. Peripheral blood concentrations of VEGF in patients with benign and malignant adrenocortical tumours in comparison with
controls (left panel) and before and after surgical treatment (right panel) (x ± SEM; *p < 0.05, ***p < 0.001, Control  =  control group)
Rycina 1. Porównanie stężeń VEGF we krwi obwodowej u chorych z łagodnymi i złośliwymi guzami nadnerczy i u osób z grupy kontrolnej
(diagram lewy) oraz przed i po leczeniu chirurgicznym (diagram prawy) (x ± SEM; *p < 0,05; ***p < 0,001; Control = grupa
kontrolna)
Figure 2. Peripheral blood concentrations of sVEGF R1 in patients with benign and malignant adrenocortical tumours in comparison
with controls (left panel) and before and after surgical treatment [right panel] (x ± SEM; *p < 0.05, Control  =  control group)
Rycina 2. Porównanie stężeń sVEGFR1 we krwi obwodowej u chorych z łagodnymi i złośliwymi guzami nadnerczy i u osób z grupy
kontrolnej (diagram lewy) oraz przed i po leczeniu chirurgicznym (diagram prawy) (x ± SEM; *p < 0,05; Control = grupa kontrolna)
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cess of new blood vessel formation that is precisely re-
gulated by pro- and anti-angiogenic cytokines, is a cri-
tical event for tumour growth and metastasis. VEGF
expression has been demonstrated by immunohistoche-
mistry in the normal adrenal medulla of the rat gland [20],
but no differences in vascular density between the nor-
mal adrenal cortex, adrenal adenomas, and carcinomas
were observed in humans using CD34 as the endothe-
lial marker [21]. VEGF mediated through its several re-
ceptors is one of the important growth factors in tumo-
ur angiogenesis [1, 5]. Peripheral blood VEGF levels may
also be abnormal in patients with some endocrine gland
neoplasms, namely: normal or high in thyroid cancers
[22–24] and increased in pituitary tumours [25]. Heday-
ati et al. [26] revealed high concentrations of VEGF and
low sVEGF receptor levels in the peripheral blood of
patients with benign and malignant thyroid tumours
as compared to controls. A number of antiangiogenic
agents targeting VEGF/VEGF-receptors are therefore
currently in pre-clinical and clinical drug trials as part
of a combined modality approach to the treatment of
cancer [1, 5, 23, 27].
In 2001 Kołomecki et al. [28] reported peripheral blo-
od concentrations of VEGF elevated above the norm in
patients with benign and malignant adrenal iniciden-
talomas before surgery, and VEGF levels were signifi-
cantly higher in subjects with malignant tumours than
in those with benign ones. Zacharieva et al. [29] found
the highest plasma levels of VEGF in adrenocortical
carcinomas, but VEGF levels were also elevated in pa-
tients with Cushing’s syndrome, primary hyperaldo-
steronism and phaeochromocytoma. Moreover, Korze-
niowska et al. [30] also demonstrated that patients with
adrenocortical carcinoma had blood VEGF levels signi-
ficantly higher and sVEGFR2 lower than a control gro-
up. On the other hand, the mean VEGF concentrations
in patients with benign adrenocortical adenoma did not
differ from those of the control group, while mean
sVEGFR1 and sVEGFR2 levels were lower than the con-
trols. In our present study, we were not able to find any
differences in the VEGF peripheral blood concentration
of patients with adrenal pathology before surgery in
comparison with controls, although higher than nor-
mal sVEGRR1 blood concentrations were noted. Others
have also found that VEGF levels inside the tumour are
significantly lower in benign adrenocortical tumours
than in adrenocortical carcinomas [31].
The results of our study show that peripheral pla-
sma blood concentrations of VEGF, sVEGFR1 and
sVEGFR2 before and after adrenalectomy cannot
discriminate between patients with benign tumours of
the adrenal cortex and those with malignant tumours
(carcinoma).
Conclusion
Peripheral blood concentrations of VEGF and its recep-
tors cannot be clinically valuable markers that discrimi-
nate between benign and malignant adrenocortical tu-
mours before and after adrenalectomy, but may be po-
tentially useful in patients with some types of adrenal
tumours who are undergoing surgery.
References
1. Folkman J. Angiogenesis:  an organizing principle for drug discovery?
Nature Rev 2007; 6: 273–285.
2. Turner ET, Harris AL, Melmed S et al. Angiogenesis in endocrine tumors.
Endocr Rev 2003; 5: 600–632.
3. Folkman J. What is the evidence that tumors are angiogenesis depen-
dent? Natl Cancer Inst 1990; 82: 4–6.
4. Jurczyńska J, Zieleniewski W, Stępień H et al. Angiogenic and anti-
-angiogenic factors in adrenal tumours. Endokrynol Pol 2006; 6: 633–640.
5. Stępień HM, Kołomecki K, Pasieka Z et al. Angiogenesis of endocrine
gland tumours — new molecular targets in diagnostics and therapy.
Eur J Endocrinol 2002; 146: 143–151.
6. Sholley M, Frguson CP, Sibel HR et al. Mechanisms of neovasculariza-
tion. Vascular sprouting can occur without proliferation of endothelial
calls. Lab Invest 1984; 51: 624–634.
7. Ferrara N. Vascular endothelial growth factor. Eur J Cancer 1996; 32A:
2413–2422.
8. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103:
211–225.
9. Aiello LP, Pierce EA, Foley ED et al. Suppression of retinal neovasculari-
sation in vitro by inhibition of vascular endothelial growth factor using
soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci 1995; 92:
10457–10461.
10. Ferrara N, Chen H, Davis-Smyth T et al. Vascular endothelial growth
factor is essential for corpus luteum angiogenesis. Nat Med 1998; 4: 336–340.
11. Lin P, Sankar S, Shan S et al. Inhibition of tumor growth by targeting
tumor endothelium using a soluble vascular endothelial growth factor.
Cell Growth Differ 1998; 9: 49–58.
12. Weidner N, Semple JP, Welch WR et al. Tumor angiogenesis and metasta-
sis:  correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1–8.
13. Weidner N, Carrol PR, Flax J et al. Tumor angiogenesis correlates
with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143:
401–409.
14. Horak ER, Leek R, Klenk N et al. Angiogenesis, assessed by platelet/en-
dothelial cell adhesion molecule antibodies, as indicator of node meta-
stases and survival in breast cancer. Lancet 1992; 340: 1120–1124.
15. Weidner N, Folkman J, Pozza F et al. Tumor angiogenesis:  a new signifi-
cant and independent prognostic indicator in early stage breast carcino-
ma. J Natl Cancer Inst 1992; 84: 1875–1887.
16. Bochner BH, Cote RJ, Weidner N et al. Angiogenesis in bladder cancer:
relationship between microvessel density and tumor prognosis. J Natl
Cancer Inst 1995; 87: 1603–1612.
17. Maeda K, Chung YS, , Takatsuka S et al. Tumor angiogenesis as a predic-
tor of recurrence in gastric carcinoma. J Clin Oncol 1995; 13: 477–481.
18. Aubert S, Wacrenier A, Leroy X et al. Weiss system revisited:  A clinico-
pathologic and immunological study of 49 adrenocortical tumors. Am
J Surg Pathol 2002; 26: 1612–1619.
19. Bovio S, Cataldi A, Reimonado G et al. Prevalence of adrenal incidentalo-
ma in a contemporary computerized tomography series. J Endocrinol
Invest 2006; 29: 298–302.
20. Fan L, Iseki S. Immunohistochemical localization of vascular endothelial
growth factor in the endocrine glands of the rat. Arch Histol Cytol 1998;
61: 17–28.
21. Sasano H, Ohashi Y, Suzuki T et al. Vascularity in human adrenal cortex.
Mod Pathol 1998; 11: 329–333.
22. Komorowski J, Pasieka Z, Jankiewicz-Wika J et al. Matrix metalloproteinases,
tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in pe-
ripheral blood of patients with thyroid cancer. Thyroid 2002; 12: 655–662.
23. Lin SY, Wang YY, Sheu WH. Preoperative plasma concentrations of va-
scular endothelial growth factor and matrix metalloproteinase 9 are asso-
ciated with stage progression in papillary thyroid cancer. Clin Endocrinl
2003; 58: 513–518.
24. Pasieka Z, Stępień H, Komorowski J et al. Evaluation of the levels of bFGF,
VEGF, sICAM-1, and sVCAM-1 in serum of patients with thyroid cancer.
Rec Res Canc Res 2003; 162: 189–194.
13
Endokrynologia Polska/Polish Journal of Endocrinology 2009; 60 (1)
PR
A
C
E 
O
R
Y
G
IN
A
LN
E
25. Komorowski J, Jankiewicz J, Stępień H. Vascular endothelial growth
factor (VEGF), basic fibroblast growth factor (bFGF) and soluble interleu-
kin-2 receptor (sIL-2R) concentrations in peripheral blood as markers of
pituitary tumors. Cytobios 2000; 101: 151–159.
26. Hedayati M, Kołomecki K, Pasieka Z et al. Assessmment of VEGF and
VEGF receptor concentrations in patients with benign and malignant
thyroid tumors. Endokrynol Pol 2005; 56: 525–528.
27. Komorowski J, Jerczyńska H, Siejka A et al. Effect of thalidomide af-
fecting VEGF secretion, cell migration, adhesion and capillary tube
formation of human endothelial EA.hy926 cells. Life Sci. 2006; 78: 2558–
–2563.
28. Kołomecki K, Stępień H, Bartos M et al. Usefulness of VEGF, MMP-2,
MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tu-
mours. Endocr Rev 2001; 35: 9–16.
29. Zacharieva S, Atanassova I, Orbetzova M et al. Circulating vascular en-
dothelial growth factor and active renin concentrations and prostaglan-
din E2 urinary excretion in patients with adrenal tumors. Eur J Endocri-
nol 2004; 150: 345–349.
30. Korzeniewska M, Kołomecki K, Stępień H et al. Assessment of pro-
and antiangiogenic factors blood serum concentrations in patients with
hormonal inactive adrenal tumors. Endokrynol Pol 2005; 56: 39–44.
31. Soon SH, McDonald KL, Robinson BG et al. Molecular markers and the
pathogenesis of adrenocortical cancer. Oncologist 2008; 13: 548–561.
